BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koch M, Treiber W, Fliser D. Effective achievement of hemoglobin stability with once-monthly C.E.R.A. in peritoneal dialysis patients: a prospective study. Clin Drug Investig 2013;33:699-706. [PMID: 23975657 DOI: 10.1007/s40261-013-0091-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Uriol-Rivera MG, Obrador-Mulet A, Jimenez-Mendoza S, Corral-Baez A, Perianez-Parraga L, Garcia-Alvarez A, de la Prada FJ. Monthly Continuous Erythropoietin Receptor Activator Versus Weekly Epoetin-Beta, Similar Hemoglobinization but Different Anisocytosis Degree in Hemodialysis Patients: A Randomized Controlled Trial. J Hematol 2021;10:255-65. [PMID: 35059087 DOI: 10.14740/jh862] [Reference Citation Analysis]
2 Schmid H. Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure. Expert Rev Hematol 2016;9:5-20. [PMID: 26573694 DOI: 10.1586/17474086.2016.1112734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
3 Budde K, Rath T, Kliem V. Anemia control in kidney transplant recipients using once-monthly continuous erythropoietin receptor activator: a prospective, observational study. J Transplant 2014;2014:179705. [PMID: 24883202 DOI: 10.1155/2014/179705] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]